TY - JOUR
T1 - Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H & N35, Phase I
AU - Singer, Susanne
AU - Arraras, Juan I.
AU - Baumann, Ingo
AU - Boehm, Andreas
AU - Chie, Wei-Chu
AU - Galalae, Razvan
AU - Langendijk, Johannes A.
AU - Guntinas-Lichius, Orlando
AU - Hammerlid, Eva
AU - Pinto, Monica
AU - Nicolatou-Galitis, Ourania
AU - Schmalz, Claudia
AU - Sen, Mehmet
AU - Sherman, Allen C.
AU - Spiegel, Karin
AU - Verdonck-de Leeuw, Irma
AU - Yarom, Noam
AU - Zotti, Paola
AU - Hofmeister, Dirk
AU - EORTC Quality Life Grp
AU - EORTC Head Neck Canc Grp
PY - 2013/9
Y1 - 2013/9
N2 - Background. The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies.Methods. The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers.Results. Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer.Conclusions. Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision. (C) 2012 Wiley Periodicals, Inc. Head Neck 35: 1331-1338, 2013
AB - Background. The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies.Methods. The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers.Results. Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer.Conclusions. Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision. (C) 2012 Wiley Periodicals, Inc. Head Neck 35: 1331-1338, 2013
KW - head and neck neoplasms
KW - larynx
KW - pharynx
KW - oral cavity
KW - multimodal therapies
KW - chemoradiation
KW - SQUAMOUS-CELL CARCINOMA
KW - EUROPEAN-ORGANIZATION
KW - RADIATION-THERAPY
KW - STAGE-III
KW - RADIOTHERAPY
KW - CISPLATIN
KW - CHEMOTHERAPY
KW - CHEMORADIATION
KW - DOCETAXEL
KW - TOXICITY
U2 - 10.1002/hed.23127
DO - 10.1002/hed.23127
M3 - Article
SN - 1043-3074
VL - 35
SP - 1331
EP - 1338
JO - Head and Neck: Journal of the Sciences and Specialties of the Head and Neck
JF - Head and Neck: Journal of the Sciences and Specialties of the Head and Neck
IS - 9
ER -